175 related articles for article (PubMed ID: 27489162)
1. Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.
An G
J Clin Pharmacol; 2017 Feb; 57(2):137-150. PubMed ID: 27489162
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.
An G; Liu W; Dutta S
J Clin Pharmacol; 2015 Oct; 55(10):1079-85. PubMed ID: 25931139
[TBL] [Abstract][Full Text] [Related]
3. General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.
Bach T; Jiang Y; Zhang X; An G
J Clin Pharmacol; 2019 Mar; 59(3):394-405. PubMed ID: 30387863
[TBL] [Abstract][Full Text] [Related]
4. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
An G
J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
[TBL] [Abstract][Full Text] [Related]
5. Target-mediated drug disposition and dynamics.
Mager DE
Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
[TBL] [Abstract][Full Text] [Related]
6. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
Gibiansky L; Gibiansky E
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
[TBL] [Abstract][Full Text] [Related]
7. Importance of Target-Mediated Drug Disposition (TMDD) of Small-Molecule Compounds and Its Impact on Drug Development-Example of the Class Effect of HSD-1 Inhibitors.
An G; Katz DA
J Clin Pharmacol; 2023 May; 63(5):526-538. PubMed ID: 36479709
[TBL] [Abstract][Full Text] [Related]
8. Target-Mediated Drug Disposition-A Class Effect of Soluble Epoxide Hydrolase Inhibitors.
An G; Lee KSS; Yang J; Hammock BD
J Clin Pharmacol; 2021 Apr; 61(4):531-537. PubMed ID: 33078430
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD) - Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding.
Xu M; An G
AAPS J; 2023 Apr; 25(3):41. PubMed ID: 37055588
[TBL] [Abstract][Full Text] [Related]
10. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
Wu N; An G
AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
[TBL] [Abstract][Full Text] [Related]
11. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
Gibiansky L; Gibiansky E; Kakkar T; Ma P
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
[TBL] [Abstract][Full Text] [Related]
12. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
13. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
Yamazaki S; Shen Z; Jiang Y; Smith BJ; Vicini P
Drug Metab Dispos; 2013 Jun; 41(6):1285-94. PubMed ID: 23557746
[TBL] [Abstract][Full Text] [Related]
14. Importance of target-mediated drug disposition for small molecules.
Smith DA; van Waterschoot RAB; Parrott NJ; Olivares-Morales A; Lavé T; Rowland M
Drug Discov Today; 2018 Dec; 23(12):2023-2030. PubMed ID: 29928850
[TBL] [Abstract][Full Text] [Related]
15. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
16. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
[TBL] [Abstract][Full Text] [Related]
17. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
18. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
Marathe A; Krzyzanski W; Mager DE
J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
[TBL] [Abstract][Full Text] [Related]
19. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
20. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.
Yan X; Chen Y; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):543-60. PubMed ID: 22926955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]